CAZypedia needs your help!
We have many unassigned pages in need of Authors and Responsible Curators. See a page that's out-of-date needs a touch-up? - you are welcome to become a CAZypedian. Here's how.
Scientists at all career stages, including students, are welcome to contribute
Read more about CAZypedia here, and in the 10th anniversary article in Glycobiology.
New to the CAZy classification? Read this first.
Difference between revisions of "User:Matthew Macauley"
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | After receiving a B.Sc. in 2003 from the University of British Columbia in Vancouver, Canada, Matthew Macauley completed a PhD in 2010 at Simon Fraser University in Burnaby, Canada under the supervision of David Vocadlo. During his graduate studies, Matthew focused on the enzymes that regulate the O-GlcNAc modification. | + | After receiving a B.Sc. in 2003 from the University of British Columbia in Vancouver, Canada, Matthew Macauley completed a PhD in 2010 at Simon Fraser University in Burnaby, Canada under the supervision of David Vocadlo. During his graduate studies, Matthew focused on the enzymes that regulate the ''O''-GlcNAc modification. These studies have led to the development of potent, selective, and cell permeable inhibitors that can modulate ''O''-GlcNAc levels ''in vivo''. Currently, Matthew is continuing in the field of glycobiology in laboratory of Jim Paulson at The Scripps Research Institute as a PostDoc where he is investigating the roles of Siglecs in the immune system. |
| + | [[Image:filename|thumb|widthpx| ]] | ||
Latest revision as of 19:29, 30 October 2010
After receiving a B.Sc. in 2003 from the University of British Columbia in Vancouver, Canada, Matthew Macauley completed a PhD in 2010 at Simon Fraser University in Burnaby, Canada under the supervision of David Vocadlo. During his graduate studies, Matthew focused on the enzymes that regulate the O-GlcNAc modification. These studies have led to the development of potent, selective, and cell permeable inhibitors that can modulate O-GlcNAc levels in vivo. Currently, Matthew is continuing in the field of glycobiology in laboratory of Jim Paulson at The Scripps Research Institute as a PostDoc where he is investigating the roles of Siglecs in the immune system.